Hasan Guven, MD
Interventional Cardiology · Birmingham, ALNPI 1770575441
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $82,188 of the $86,153 with a category attached, or 95.4%. Boston Scientific accounts for 95.8% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $52,739, more than ten times the $556 reported in 2019. Among interventional cardiology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 237 payments — averaging $363.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$83K
- Novartis$968
- Pfizer$298
- Novo Nordisk$270
- Inari Medical, Inc.$253
- Amgen$235
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$82,18895%
- Food & beverage$3,9665%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 40 | $82,575 |
| Novartis | 82 | $968 |
| Pfizer | 16 | $298 |
| Novo Nordisk | 18 | $270 |
| Inari Medical, Inc. | 3 | $253 |
| Amgen | 17 | $235 |
| E.r. Squibb & Sons, L.L.C. | 11 | $187 |
| Ancora Heart, Inc. | 1 | $181 |
| Celonova Biosciences, Inc. | 1 | $142 |
| Livanova USA, Inc. | 1 | $130 |
| Johnson & Johnson | 8 | $110 |
| Abbott | 5 | $107 |
| Sanofi-aventis U.S. LLC | 6 | $102 |
| Abiomed | 1 | $100 |
| Biosense Webster, Inc. | 1 | $76 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $70 |
| Irhythm Technologies, Inc. | 4 | $70 |
| Medtronic | 2 | $40 |
| CSL Behring | 2 | $40 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Bayer | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Impulse Dynamics (USA) Inc. | 1 | $17 |
| Lantheus Medical Imaging, Inc. | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $16 |
| GSK | 1 | $15 |
| Akcea Therapeutics, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$52,955
- Watchman$29,375
- AccuCinch$181
- FlowTriever$151
- ClotTriever$151
- TandemLife$130
- Impella$100
How this compares
$86,153 in reported general payments places this provider in the 95th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 468 | $465,480 |
| EntrestoSacubitril/Valsartan | 162 | $147,380 |
| XareltoRivaroxaban | 117 | $111,252 |
| Repatha SureclickEvolocumab | 103 | $79,845 |
| MultaqDronedarone Hcl | 36 | $52,934 |
| FarxigaDapagliflozin Propanediol | 60 | $41,259 |
| JardianceEmpagliflozin | 49 | $36,689 |
| Praluent PenAlirocumab | 16 | $12,384 |
| Ranolazine ErRanolazine | 74 | $9,521 |
| Icosapent Ethyl | 17 | $6,290 |
| Atorvastatin Calcium | 423 | $6,113 |
| Flecainide Acetate | 54 | $5,595 |
| Metoprolol Succinate | 385 | $5,282 |
| Ezetimibe | 115 | $3,554 |
| Carvedilol | 342 | $3,378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $298 | $465,480468 claims |
| NovartisEntresto | $968 | $147,380162 claims |
| Johnson & JohnsonXarelto | $110 | $111,252117 claims |
| Sanofi-aventis U.S. LLCMultaq | $102 | $52,93436 claims |
| AstraZenecaFarxiga | $11 | $41,25960 claims |
| Boehringer IngelheimJardiance | $16 | $36,68949 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Birmingham
- Gary RoubinBirmingham$157K
- Robert FosterBirmingham$90K
- Abdullah MahmoodBirmingham$61K
- Ali EbrahimiBirmingham$55K
- Jacob TownsendBirmingham$52K
- Kamran AliBirmingham$47K
- Mouhamed SabouniBirmingham$44K
- David SchultzBirmingham$19K
- Tushar MishraBirmingham$17K
- Arka ChatterjeeBirmingham$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.